Fairmount Funds Management
Latest statistics and disclosures from Fairmount Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are COGT, APGE, SYRE, VRDN, ORKA, and represent 63.95% of Fairmount Funds Management's stock portfolio.
- Added to shares of these 5 stocks: JBIO (+$21M), CBIO (+$16M), VRDN (+$14M), ZBIO (+$12M), IKT (+$5.1M).
- Reduced shares in these 6 stocks: AXSM (-$99M), SRRK (-$68M), ABVX (-$61M), DNTH (-$48M), Astria Therapeutics (-$26M), KNSA (-$19M).
- Sold out of its positions in ABVX, Astria Therapeutics, AXSM, SRRK.
- Fairmount Funds Management was a net seller of stock by $-253M.
- Fairmount Funds Management has $1.3B in assets under management (AUM), dropping by 18.21%.
- Central Index Key (CIK): 0001802528
Tip: Access up to 7 years of quarterly data
Positions held by Fairmount Funds Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 13 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cogent Biosciences (COGT) | 24.3 | $320M | 9.0M | 35.52 |
|
|
| Apogee Therapeutics (APGE) | 11.8 | $155M | 2.0M | 75.48 |
|
|
| Spyre Therapeutics Com New (SYRE) | 10.0 | $132M | 4.0M | 32.76 |
|
|
| Miragen Therapeutics (VRDN) | 9.3 | $122M | +13% | 3.9M | 31.12 |
|
| Oruka Therapeutics (ORKA) | 8.5 | $112M | 3.7M | 30.31 |
|
|
| Dianthus Therapeutics (DNTH) | 6.7 | $88M | -35% | 2.1M | 41.21 |
|
| Zenas Biopharma (ZBIO) | 6.1 | $80M | +16% | 2.2M | 36.31 |
|
| Nuvalent Inc-a (NUVL) | 5.6 | $73M | 728k | 100.59 |
|
|
| Jade Biosciences Com New (JBIO) | 5.3 | $70M | +41% | 4.6M | 15.43 |
|
| Enliven Therapeutics (ELVN) | 4.4 | $57M | 3.7M | 15.40 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 4.1 | $54M | -25% | 1.3M | 41.25 |
|
| Crescent Biopharma (CBIO) | 2.5 | $33M | +97% | 2.7M | 11.86 |
|
| Inhibikase Therapeutics Com New (IKT) | 1.3 | $18M | +40% | 8.6M | 2.05 |
|
Past Filings by Fairmount Funds Management
SEC 13F filings are viewable for Fairmount Funds Management going back to 2019
- Fairmount Funds Management 2025 Q4 filed Feb. 17, 2026
- Fairmount Funds Management 2025 Q3 filed Nov. 14, 2025
- Fairmount Funds Management 2025 Q2 filed Aug. 14, 2025
- Fairmount Funds Management 2025 Q1 filed May 15, 2025
- Fairmount Funds Management 2024 Q4 filed Feb. 14, 2025
- Fairmount Funds Management 2024 Q3 filed Nov. 14, 2024
- Fairmount Funds Management 2024 Q2 filed Aug. 14, 2024
- Fairmount Funds Management 2024 Q1 filed May 15, 2024
- Fairmount Funds Management 2023 Q4 filed Feb. 14, 2024
- Fairmount Funds Management 2023 Q3 filed Nov. 14, 2023
- Fairmount Funds Management 2023 Q2 filed Aug. 14, 2023
- Fairmount Funds Management 2023 Q1 filed May 15, 2023
- Fairmount Funds Management 2022 Q4 filed Feb. 14, 2023
- Fairmount Funds Management 2022 Q3 filed Nov. 9, 2022
- Fairmount Funds Management 2022 Q2 filed Aug. 15, 2022
- Fairmount Funds Management 2022 Q1 filed May 16, 2022